Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review

被引：24
|
作者：
Blayney, Douglas W. [1 ,3 ]
Schwartzberg, Lee [2 ]
机构：
[1] Stanford Canc Inst, Stanford, CA 75216 USA
[2] Univ Nevada, Renown Inst Canc, Reno, NV USA
[3] 875 Blake Wilbur Dr,Room CC-2219,M-C 6576, Stanford, CA 94305 USA
来源：
CANCER TREATMENT REVIEWS | 2022年 / 109卷
关键词：
Chemotherapy -induced neutropenia; G-CSF; Trilaciclib; Plinablin; Efbemalenograstim alpha; Eflapegrastim; INDUCED FEBRILE NEUTROPENIA; COLONY-STIMULATING FACTOR; RELATIVE DOSE INTENSITY; PER-CYCLE PEGFILGRASTIM; US CLINICAL-PRACTICE; BREAST-CANCER; PRIMARY PROPHYLAXIS; PLINABULIN PLIN; BIOSIMILAR FILGRASTIM; RECEIVING CHOP;
D O I：
10.1016/j.ctrv.2022.102427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：10
相关论文
共 50 条
  • [21] Management of chemotherapy-induced neutropenia
    Blundell, Bernardette
    Azzopardi, Lilian M.
    Serracino-Inglott, Anthony
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (01) : 241 - 241
  • [22] Expanding research and development of novel agents for the treatment and prevention of chemotherapy-induced alopecia
    Han, Amy
    Poulos, Georgann Anetakis
    Mirmirani, Paradi
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (06) : 773 - 781
  • [23] Economic evaluations of granulocyte colony-stimulating factorIn the prevention and treatment of chemotherapy-induced neutropenia
    Marc Esser
    Helmut Brunner
    PharmacoEconomics, 2003, 21 : 1295 - 1313
  • [24] Economic evaluations of granulocyte colony-stimulating factor - In the prevention and treatment of chemotherapy-induced neutropenia
    Esser, M
    Brunner, H
    PHARMACOECONOMICS, 2003, 21 (18) : 1295 - 1313
  • [25] Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors
    Lambertini, Matteo
    Ferreira, Arlindo R.
    Del Mastro, Lucia
    Danesi, Romano
    Pronzato, Paolo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (12) : 1799 - 1817
  • [26] RecombinantGanoderma lucidumImmunomodulatory Protein Improves the Treatment for Chemotherapy-Induced Neutropenia
    Lei, Xinhua
    Zhi, Chenyang
    Huang, Wei
    Sun, Xilin
    Gao, Weiyang
    Yin, Xue
    Zhang, Xin
    Liang, Chongyang
    Zhang, Haoran
    Sun, Fei
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [27] New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
    Ghidini, Michele
    Hahne, Jens Claus
    Trevisani, Francesco
    Panni, Stefano
    Ratti, Margherita
    Toppo, Laura
    Tomasello, Gianluca
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1009 - 1015
  • [28] Chemotherapy-induced neutropenia and febrile neutropenia during chemotherapy for gynaecologic malignancy
    Hashiguchi, Y.
    Fukuda, T.
    Ichimura, T.
    Matsumoto, Y.
    Yasui, T.
    Sumi, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S277 - S277
  • [29] Prevention and treatment of chemotherapy-induced peripheral neuropathy
    Piccolo, Jennifer
    Kolesar, Jill M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (01) : 19 - 25
  • [30] Chemotherapy-Induced Peripheral Neuropathy: Prevention and Treatment
    Pachman, D. R.
    Barton, D. L.
    Watson, J. C.
    Loprinzi, C. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (03) : 377 - 387
12345